Compare TREE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREE | AKBA |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.5M | 343.4M |
| IPO Year | 2008 | 2014 |
| Metric | TREE | AKBA |
|---|---|---|
| Price | $25.91 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $71.25 | $4.67 |
| AVG Volume (30 Days) | 387.4K | ★ 8.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 443.31 | 93.94 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,117,324,000.00 | N/A |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $13.69 | ★ N/A |
| Revenue Growth | ★ 24.12 | N/A |
| 52 Week Low | $25.98 | $0.81 |
| 52 Week High | $74.53 | $3.19 |
| Indicator | TREE | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 30.37 | 42.56 |
| Support Level | N/A | $0.84 |
| Resistance Level | $39.74 | $0.96 |
| Average True Range (ATR) | 1.03 | 0.06 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 9.56 | 25.62 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.